BETting on the future: BET inhibition for patients with lymphoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: lymphoma may still develop relapsed or refractory diseases, highlighting the need for new therapies
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
report a phase I dose-escalation study of TQB3617, a novel BET inhibitor, in diverse lymphoma subtypes. The study showed promising safety and efficacy, including T cell and Hodgkin lymphoma, warranting further investigation.
Despite available treatments, patients with lymphoma may still develop relapsed or refractory diseases, highlighting the need for new therapies.
APA
Voorhees TJ, Coombs CC (2026). BETting on the future: BET inhibition for patients with lymphoma.. Med (New York, N.Y.), 7(1), 100955. https://doi.org/10.1016/j.medj.2025.100955
MLA
Voorhees TJ, et al.. "BETting on the future: BET inhibition for patients with lymphoma.." Med (New York, N.Y.), vol. 7, no. 1, 2026, pp. 100955.
PMID
41519111
Abstract
Despite available treatments, patients with lymphoma may still develop relapsed or refractory diseases, highlighting the need for new therapies. Zhang et al. report a phase I dose-escalation study of TQB3617, a novel BET inhibitor, in diverse lymphoma subtypes. The study showed promising safety and efficacy, including T cell and Hodgkin lymphoma, warranting further investigation.